DaVita Inc.

Healthcare · Medical - Care Facilities

Overall research band Weak

Quality Weak

Valuation Weak

Balance sheet Very weak

Market confirmation Weak

One-minute company read

What this report can tell you now

What the company does

DaVita Inc. is a healthcare company specializing in kidney dialysis treatments and comprehensive renal care for individuals with chronic kidney failure and end-stage renal disease (ESRD). The company operates a large network of outpatient dialysis centers in the United States and internationally, provides dialysis services in hospital inpatient settings and patients' homes, and manages its own diagnostic laboratories for routine and physician-ordered tests. DaVita also offers administrative and management support to other outpatient dialysis facilities, chronic disease management programs, vascular access interventions, clinical research, physician support, and holistic kidney care solutions. Its primary customers are patients requiring dialysis and related renal care, with revenue generated through the provision of these medical services. As of December 31, 2021, DaVita served approximately 203,100 patients in 2,815 U.S. outpatient centers and about 39,900 patients in 339 centers across ten countries outside the U.S.

The current research profile is Deep Value, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC12.6%Model input; read with the evidence status and period context.

Operating margin14.7%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years4.1%Model input; read with the evidence status and period context.

FCF margin9.6%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.